Vivek Kumar Vyas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vivek Kumar Vyas has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Manjunath Ghate
Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India
28 shared publications - Hardik Girishkumar Bhatt
Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad, India
5 shared publications Pinky Gehlot
5 shared publications- Tejas M. Dhameliya
Department of Pharmaceutical Chemistry Institute of Pharmacy Nirma University Ahmedabad Gujarat 382 481 India
5 shared publications - Chetan Chintha
Apoptosis Research Centre, National University of Ireland Galway, Galway, Ireland
4 shared publications Gulamnizami Qureshi
4 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by KEAI Publishing in Letters in Drug Design & Discovery
- Vol. 23 (1)
Rational design of novel 2-aminopyrido[3,4-d]pyrimidin-4-one derivatives as Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors using 3D QSAR, docking, and molecular dynamics simulation approaches
- 1 January 2026
- Published by KEAI Publishing in Letters in Drug Design & Discovery
- Vol. 23 (1)
Open AccessRational design of novel 2-aminopyrido[3,4-d]pyrimidin-4-one derivatives as Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors using 3D QSAR, docking, and molecular dynamics simulation approaches
- 22 September 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (36)
In Search of PI3K Inhibitors as Anticancer Agents: Molecular Modelling Through Virtual Screening, ADMET, and Molecular Dynamics Simulations
Cancer remains one of the leading causes of death worldwide, with current therapies often limited by side effects, recurrence of metastatic cancer, and poor patient compliance. The urgent need for new anticancer agents with novel mechanisms of action has made phosphoinositide 3‐kinase (PI3K) a promising target due to its role in cell growth, proliferation, and survival. In this study, we employed a comprehensive computational approach, beginning with the generation of a 3D pharmacophore model of PI3K using atomic property field (APF) alignment of two crystal structures (PDB IDs: 4L23 and 8TSC). Virtual screening of 2,500 MolScreen ligands and 2,431,025 ChEMBL ligands was performed, identifying 350 ligands with promising interactions with PI3K. ADMET analysis and docking scores were calculated for these, and 200 ligands showed favorable pharmacokinetic or drug‐like properties. Among them, CHEMBL2163908 emerged as the top candidate, exhibiting the highest docking score and promising drug‐likeness properties. Further molecular dynamics (MD) simulations of CHEMBL2163908 for 200 ns confirmed its stable binding at the PI3K active site. These findings highlight CHEMBL2163908 as a potential lead for the development of novel PI3K inhibitors in anticancer therapy.
- 22 September 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (36)
In Search of PI3K Inhibitors as Anticancer Agents: Molecular Modelling Through Virtual Screening, ADMET, and Molecular Dynamics Simulations
Cancer remains one of the leading causes of death worldwide, with current therapies often limited by side effects, recurrence of metastatic cancer, and poor patient compliance. The urgent need for new anticancer agents with novel mechanisms of action has made phosphoinositide 3‐kinase (PI3K) a promising target due to its role in cell growth, proliferation, and survival. In this study, we employed a comprehensive computational approach, beginning with the generation of a 3D pharmacophore model of PI3K using atomic property field (APF) alignment of two crystal structures (PDB IDs: 4L23 and 8TSC). Virtual screening of 2,500 MolScreen ligands and 2,431,025 ChEMBL ligands was performed, identifying 350 ligands with promising interactions with PI3K. ADMET analysis and docking scores were calculated for these, and 200 ligands showed favorable pharmacokinetic or drug‐like properties. Among them, CHEMBL2163908 emerged as the top candidate, exhibiting the highest docking score and promising drug‐likeness properties. Further molecular dynamics (MD) simulations of CHEMBL2163908 for 200 ns confirmed its stable binding at the PI3K active site. These findings highlight CHEMBL2163908 as a potential lead for the development of novel PI3K inhibitors in anticancer therapy.
- 7 June 2025
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1344
Novel benzophenone-, acetophenone-, and benzohydrazide-containing triazolopyrimidines as inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH): Design utilizing combined in silico approaches, synthesis, in vitro enzyme inhibition, and in vivo antimalarial activity
- 7 June 2025
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1344
Novel benzophenone-, acetophenone-, and benzohydrazide-containing triazolopyrimidines as inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH): Design utilizing combined in silico approaches, synthesis, in vitro enzyme inhibition, and in vivo antimalarial activity
- 3 June 2025
- Published by Taylor & Francis in SAR and QSAR in Environmental Research
- Vol. 36 (6) , 487-506
Design of novel imidazo[1,2- a ]pyrimidines as Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors using fragment-based and other integrated in silico approaches
Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) is a well-established target for developing novel antimalarial agents. Novel imidazo[1,2-a]pyrimidines were designed as PfDHODH inhibitors using a fragment-based drug design (FADD) approach. A library of active molecules targeting PfDHODH was analysed to generate fragments using the RDKit BRICS module. These fragments were screened by docking them into the active site of the PfDHODH enzyme. Among them, the lead fragment, fragment-11, demonstrated a significant binding affinity of -6.895 kcal/mol. This fragment was optimized using a fragment-growing approach via the FragGrow webserver. From the 471 generated molecules, two showed binding scores of -7.9 and -7.0 kcal/mol. These molecules were further optimized, resulting in a lead molecule with a binding score of -11.3 kcal/mol. Based on the results from the FragGrow webserver, 216 novel imidazo[1,2-a]pyrimidines were designed using the scaffold-hopping approach. The ADMET properties of these compounds revealing that all the designed compounds exhibited drug-like properties. Docking studies indicated that compounds 28d, 46d, and 49d had strong binding affinities, with 28d showing the highest score of -10.41 kcal/mol. Furthermore, molecular dynamics (MD) simulations of 28d demonstrated good stability in the enzyme-ligand complex. This comprehensive in silico study suggests that imidazo[1,2-a]pyrimidines can serve as potent PfDHODH inhibitors.
- 3 June 2025
- Published by Taylor & Francis in SAR and QSAR in Environmental Research
- Vol. 36 (6) , 487-506
Design of novel imidazo[1,2- a ]pyrimidines as Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors using fragment-based and other integrated in silico approaches
Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) is a well-established target for developing novel antimalarial agents. Novel imidazo[1,2-a]pyrimidines were designed as PfDHODH inhibitors using a fragment-based drug design (FADD) approach. A library of active molecules targeting PfDHODH was analysed to generate fragments using the RDKit BRICS module. These fragments were screened by docking them into the active site of the PfDHODH enzyme. Among them, the lead fragment, fragment-11, demonstrated a significant binding affinity of -6.895 kcal/mol. This fragment was optimized using a fragment-growing approach via the FragGrow webserver. From the 471 generated molecules, two showed binding scores of -7.9 and -7.0 kcal/mol. These molecules were further optimized, resulting in a lead molecule with a binding score of -11.3 kcal/mol. Based on the results from the FragGrow webserver, 216 novel imidazo[1,2-a]pyrimidines were designed using the scaffold-hopping approach. The ADMET properties of these compounds revealing that all the designed compounds exhibited drug-like properties. Docking studies indicated that compounds 28d, 46d, and 49d had strong binding affinities, with 28d showing the highest score of -10.41 kcal/mol. Furthermore, molecular dynamics (MD) simulations of 28d demonstrated good stability in the enzyme-ligand complex. This comprehensive in silico study suggests that imidazo[1,2-a]pyrimidines can serve as potent PfDHODH inhibitors.
- 15 May 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (19)
Investigations Through In Silico Molecular Modelling Against Falcipain‐2 in Search of Potent Anti‐Malarial Agents
Malaria remains a major global health concern, exacerbated by the increasing resistance of Plasmodium falciparum to existing anti‐malarial drugs. This growing challenge necessitates the urgent discovery of novel therapeutic agents targeting unexplored biological pathways. Falcipain‐2, a cysteine protease involved in hemoglobin metabolism during the erythrocytic stage, has emerged as the promising and key drug target. The current state of resistance to malaria treatments has made it imperative to find new anti‐malarial drugs using in silico tools driven by computer aided drug design. A virtual screening of 91,001 ligands from the Asinex Elite Synergy 2021–02 library has been performed using AutoDock Vina, yielding 20 hits with superior binding affinities (−10.0 to −9.7 kcal/mol) compared to the reference inhibitor, E64 (−5.8 kcal/mol). Further evaluation of their pharmacokinetic and toxicity profiles confirmed their favorable ADMET properties, suggesting high oral bioavailability and drug‐likeness. The stability of the top two identified compounds in complex with Falcipain‐2 was further validated through molecular dynamics (MD) simulations over 100 ns using GROMACS. These findings highlight the efficacy of computational strategies in accelerating anti‐malarial drug discovery and provide a strong foundation for the development of next‐generation therapeutics targeting drug‐resistant malaria.
- 15 May 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (19)
Investigations Through In Silico Molecular Modelling Against Falcipain‐2 in Search of Potent Anti‐Malarial Agents
Malaria remains a major global health concern, exacerbated by the increasing resistance of Plasmodium falciparum to existing anti‐malarial drugs. This growing challenge necessitates the urgent discovery of novel therapeutic agents targeting unexplored biological pathways. Falcipain‐2, a cysteine protease involved in hemoglobin metabolism during the erythrocytic stage, has emerged as the promising and key drug target. The current state of resistance to malaria treatments has made it imperative to find new anti‐malarial drugs using in silico tools driven by computer aided drug design. A virtual screening of 91,001 ligands from the Asinex Elite Synergy 2021–02 library has been performed using AutoDock Vina, yielding 20 hits with superior binding affinities (−10.0 to −9.7 kcal/mol) compared to the reference inhibitor, E64 (−5.8 kcal/mol). Further evaluation of their pharmacokinetic and toxicity profiles confirmed their favorable ADMET properties, suggesting high oral bioavailability and drug‐likeness. The stability of the top two identified compounds in complex with Falcipain‐2 was further validated through molecular dynamics (MD) simulations over 100 ns using GROMACS. These findings highlight the efficacy of computational strategies in accelerating anti‐malarial drug discovery and provide a strong foundation for the development of next‐generation therapeutics targeting drug‐resistant malaria.
- 17 December 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (47)
Evolution of Telomerase Inhibitors: A Review on Key Patents from 2015 to 2023
Telomerase (TERT) is a ribonucleoprotein that regulates telomere length and maintains chromosomal integrity. TERT is a widely expressed protein for replicative immortality in most malignant tumours. TERT is a protein produced by cancer cells that prevents telomere shortening by adding telomere sequences beyond the Hayflick limit, allowing them to divide in an uncontrolled manner. Inhibition of the TERT enzyme is a recognised therapy for treating cancer. The basic objective of the review is to collectively represent the current scenario of treating cancer by inhibiting TERT. With a focus on the recently patented TERT inhibitors and clinical trial data released between 2015 and 2023, this review highlights the work relevant to the development of TERT inhibitors. Furthermore, recent advancements in the clinical development of TERT inhibitors, along with prospective new combinations, are also discussed. The use of TERT inhibitors in cancer therapy has been granted with great interest and significant attention by researchers along with a promising outcome in terms of therapeutic value. Several clinical trial applications and their data gave strong evidence of the use of TERT inhibitors for cancer therapy which provided target therapies, vaccine therapies, nucleoside, non‐nucleoside therapies, and so forth with reduced side effects and enhanced potency.
- 17 December 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (47)
Evolution of Telomerase Inhibitors: A Review on Key Patents from 2015 to 2023
Telomerase (TERT) is a ribonucleoprotein that regulates telomere length and maintains chromosomal integrity. TERT is a widely expressed protein for replicative immortality in most malignant tumours. TERT is a protein produced by cancer cells that prevents telomere shortening by adding telomere sequences beyond the Hayflick limit, allowing them to divide in an uncontrolled manner. Inhibition of the TERT enzyme is a recognised therapy for treating cancer. The basic objective of the review is to collectively represent the current scenario of treating cancer by inhibiting TERT. With a focus on the recently patented TERT inhibitors and clinical trial data released between 2015 and 2023, this review highlights the work relevant to the development of TERT inhibitors. Furthermore, recent advancements in the clinical development of TERT inhibitors, along with prospective new combinations, are also discussed. The use of TERT inhibitors in cancer therapy has been granted with great interest and significant attention by researchers along with a promising outcome in terms of therapeutic value. Several clinical trial applications and their data gave strong evidence of the use of TERT inhibitors for cancer therapy which provided target therapies, vaccine therapies, nucleoside, non‐nucleoside therapies, and so forth with reduced side effects and enhanced potency.